Blue Jet Healthcare (NSE: BLUEJET) Surges 8.5% After Raising ₹800 Crore Through QIP at ₹506 Per Share

Blue Jet Healthcare shares jumped as much as 8.5% on July 10, 2026. The rally followed the company’s ₹800 crore fundraise through a Qualified Institutional Placement. Blue Jet Healthcare allotted 15,810,276 equity shares at ₹506 each, a discount to the floor price. The QIP window ran from July 6 to July 9, 2026, before the board approved final allotment. Investors welcomed the capital raise as a step toward funding the company’s expansion plans.

How the Blue Jet Healthcare QIP Was Priced

Blue Jet Healthcare (BLUEJET.NS) fixed the QIP floor price at ₹531.70 per share on July 6, 2026. The final issue price came in at ₹506, a discount of ₹25.70 to that floor. That discount worked out to roughly 4.83%, staying within the 5% cap shareholders approved. The company issued shares with a face value of ₹2 each under the placement. Total proceeds from the offering reached ₹800 crore once allotment closed on July 9.

• QIP floor price: ₹531.70 per share, set on July 6, 2026.
• Final issue price: ₹506 per share, a discount of ₹25.70.
• Shares allotted: 15,810,276 equity shares, or 1.58 crore shares.
• Total capital raised: ₹800 crore through the placement window.

Why Blue Jet Healthcare Stock Reacted Strongly

Blue Jet Healthcare shares gained as much as 8% intraday and traded 5% higher at the opening bell. The stock had already climbed more than 22% over the prior month heading into the QIP. Blue Jet Healthcare’s market capitalization stood near ₹9,897 crore as of July 7, 2026, before the raise. 

#BlueJetHealthcare raises ₹800 crore via #QIP, two institutions get nearly 67% of shares@ShlokaBadkar https://t.co/izzXl2bB4s

— CNBC-TV18 (@CNBCTV18Live) July 10, 2026

Shares remain down over 36% across the past year, though 2026 year-to-date gains stand at 8%. The successful QIP closure removed fundraising uncertainty that had weighed on sentiment.

Recent Blue Jet Healthcare Price Milestones

• 52-week high: ₹1,027.80, recorded on July 21, 2025.
• 52-week low: ₹325.00, recorded on March 30, 2026.
• Pre-QIP market cap: approximately ₹9,897 crore as of July 7, 2026.
• One-month gain heading into the raise: more than 22%.

Blue Jet Healthcare’s Recent Financial Backdrop

Blue Jet Healthcare posted a standalone net profit of ₹64.34 crore in Q4 FY26, down 41.56% year-on-year. That figure still marked a 60.17% jump from the prior quarter. Revenue from operations fell 31.07% year-on-year to ₹234.67 crore, hurt by weak sales in one PI vertical molecule. Sequentially, however, revenue rose 21.96%, driven by stronger advanced contrast media sales. 

The QIP proceeds arrive at a moment when the company needs capital to support its manufacturing pipeline.

What the QIP Funds Are Meant to Support

• A planned ₹1,000 crore manufacturing facility in Vizag, Andhra Pradesh.
• Broader capacity expansion across the company’s CDMO operations.
• Working capital needs following a volatile earnings quarter.
• Strategic flexibility as the company competes with CDMO peers.

Blue Jet Healthcare’s Position in the CDMO Space

Blue Jet Healthcare operates as a specialty pharmaceutical and healthcare ingredient company. It functions as an end-to-end integrated Contract Development and Manufacturing Organisation, competing alongside CDMO names like Divi’s Laboratories (DIVISLAB.NS) and Suven Pharmaceuticals (SUVENPHAR.NS). The QIP strengthens its balance sheet as it scales up advanced contrast media and specialty ingredient production. Company management had flagged plans for a roughly ₹1,000 crore fundraise back in its Q4 FY26 results.

Final Thoughts

Blue Jet Healthcare’s ₹800 crore QIP at ₹506 per share gives the company fresh capital heading into its next growth phase. The 8.5% stock surge reflects investor confidence in the company’s Vizag expansion and CDMO growth strategy. With the fundraise now complete, attention shifts to how quickly Blue Jet Healthcare can convert this capital into revenue growth. The coming quarters will show whether this rally has lasting support.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice